Duquette André, Frenette Anne Julie, Doré Maxime
Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.
Department of Pharmacy, Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada.
Rheumatol Ther. 2016 Jun;3(1):179-185. doi: 10.1007/s40744-016-0025-3. Epub 2016 Jan 20.
To report the case of a patient treated with leflunomide that presented with chronic diarrhea associated with high teriflunomide blood concentration. An 84-year-old woman taking leflunomide 20 mg once daily for the past 2 years to treat rheumatoid arthritis (RA) was investigated for severe chronic diarrhea that had been worsening for the past 5 months. The patient's general condition progressively deteriorated and included electrolyte imbalances and a transient loss of consciousness. Therefore, hospitalization was required. Teriflunomide blood concentration was 156 mg/L. After 11 days of cholestyramine washout therapy, teriflunomide blood concentration was reduced to 6 mg/L. As the teriflunomide levels decreased, diarrhea improved. All other possible causes of diarrhea were ruled out. The patient's diarrhea finally resolved 26 days after treatment with cholestyramine.
Diarrhea is a known adverse effect of leflunomide. In this report, the severe diarrhea was associated with high blood teriflunomide concentrations. Available data suggests an association between teriflunomide concentrations greater than 50 mg/L and lower disease activity, but toxic teriflunomide levels still have to be clarified.
Further studies are needed to establish the optimal therapeutic levels of teriflunomide. However, therapeutic drug monitoring of teriflunomide blood concentrations may be helpful to improve effectiveness and to prevent toxicity in patients taking leflunomide for RA, particularly in those with suboptimal therapeutic response to leflunomide or in patients with toxicity suspected to be induced by leflunomide.
报告一例使用来氟米特治疗的患者出现慢性腹泻且血液中替格瑞洛浓度较高的病例。一名84岁女性,在过去2年中每天服用20毫克来氟米特治疗类风湿关节炎(RA),因过去5个月来严重慢性腹泻病情逐渐加重而接受调查。患者的一般状况逐渐恶化,包括电解质失衡和短暂意识丧失。因此,需要住院治疗。替格瑞洛血液浓度为156毫克/升。经过11天的消胆胺洗脱治疗后,替格瑞洛血液浓度降至6毫克/升。随着替格瑞洛水平下降,腹泻有所改善。排除了所有其他可能导致腹泻的原因。患者在接受消胆胺治疗26天后腹泻最终缓解。
腹泻是来氟米特已知的不良反应。在本报告中,严重腹泻与血液中替格瑞洛高浓度有关。现有数据表明,替格瑞洛浓度大于50毫克/升与较低的疾病活动度之间存在关联,但替格瑞洛的毒性水平仍有待明确。
需要进一步研究以确定替格瑞洛的最佳治疗水平。然而,对服用来氟米特治疗RA的患者进行替格瑞洛血液浓度的治疗药物监测可能有助于提高疗效并预防毒性,特别是对于那些如来氟米特治疗反应欠佳或怀疑有毒性由来氟米特引起的患者。